PL336415A1 - Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors - Google Patents

Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors

Info

Publication number
PL336415A1
PL336415A1 PL98336415A PL33641598A PL336415A1 PL 336415 A1 PL336415 A1 PL 336415A1 PL 98336415 A PL98336415 A PL 98336415A PL 33641598 A PL33641598 A PL 33641598A PL 336415 A1 PL336415 A1 PL 336415A1
Authority
PL
Poland
Prior art keywords
ileic
benzothiepins
hmg
well
bile acid
Prior art date
Application number
PL98336415A
Other languages
English (en)
Inventor
David B Reitz
Len F Lee
Jinglin J Li
Horng-Chih Huang
Samuel J Tremont
Raymond E Miller
Shyamal C Baneriee
Robert E Manning
Kevin C Glenn
Bradley T Keller
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL336415(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of PL336415A1 publication Critical patent/PL336415A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL98336415A 1997-03-11 1998-03-10 Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors PL336415A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4066097P 1997-03-11 1997-03-11
PCT/US1998/003792 WO1998040375A2 (en) 1997-03-11 1998-03-10 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Publications (1)

Publication Number Publication Date
PL336415A1 true PL336415A1 (en) 2000-06-19

Family

ID=21912237

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98336415A PL336415A1 (en) 1997-03-11 1998-03-10 Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors

Country Status (16)

Country Link
EP (1) EP0971744A2 (enExample)
JP (1) JP2002500628A (enExample)
CN (1) CN1255864A (enExample)
AU (1) AU730024C (enExample)
BG (1) BG103793A (enExample)
BR (1) BR9808013A (enExample)
CA (1) CA2283575A1 (enExample)
HU (1) HUP0002395A3 (enExample)
IL (1) IL131872A0 (enExample)
MX (1) MXPA99008417A (enExample)
NO (1) NO994390L (enExample)
NZ (1) NZ337830A (enExample)
PL (1) PL336415A1 (enExample)
RU (1) RU2247579C2 (enExample)
SK (1) SK125099A3 (enExample)
WO (1) WO1998040375A2 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
AU2003241629B2 (en) * 1999-04-19 2005-06-16 Astrazeneca Ab An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002051396A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
MY131995A (en) 2001-09-08 2007-09-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
CN1596240A (zh) 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
WO2004020421A1 (ja) * 2002-08-28 2004-03-11 Asahi Kasei Pharma Corporation 新規な４級アンモニウム化合物
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AU2005217318B2 (en) 2004-02-27 2010-07-01 Asahi Kasei Pharma Corporation Novel benzothiazepine and benzothiepine compounds
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
CN106794188B (zh) 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CA3011595C (en) 2016-02-09 2024-01-02 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP4424363B1 (en) 2019-02-12 2026-04-29 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease
JP7665621B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158195A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN112274648B (zh) * 2020-11-23 2022-10-14 郑州大学 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh) 2021-06-03 2024-01-16 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4536232A1 (en) 2022-06-09 2025-04-16 Albireo AB Treating hepatitis
TW202423921A (zh) * 2022-08-22 2024-06-16 美商安塔製藥公司 稠合的雜雙環抗病毒劑
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
FI108451B (fi) * 1991-12-20 2002-01-31 Hoechst Ag Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds

Also Published As

Publication number Publication date
MXPA99008417A (es) 2005-02-03
EP0971744A2 (en) 2000-01-19
NO994390L (no) 1999-11-04
CA2283575A1 (en) 1998-09-17
SK125099A3 (en) 2001-02-12
BG103793A (en) 2000-07-31
NO994390D0 (no) 1999-09-10
AU6440898A (en) 1998-09-29
RU2247579C2 (ru) 2005-03-10
AU730024C (en) 2004-08-05
HUP0002395A2 (hu) 2001-05-28
NZ337830A (en) 2001-07-27
WO1998040375A3 (en) 1998-12-03
BR9808013A (pt) 2001-09-25
AU730024B2 (en) 2001-02-22
CN1255864A (zh) 2000-06-07
JP2002500628A (ja) 2002-01-08
HUP0002395A3 (en) 2002-12-28
WO1998040375A2 (en) 1998-09-17
IL131872A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
GB2351077B (en) Improved acid corrosion inhibitor
HUP0002395A3 (en) Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
MXPA01013406A (es) Compuestos inhibidores de vla-4.
AU8654598A (en) Steel alloy for compound tubes
MXPA03003417A (es) Formulacion oral que comprende un compuesto inhibidor del transporte biliar ileal y un inhibidor de reductasa hmgco-a.
ZA9811794B (en) Ace inhibitor-MMP inhibitor combinations.
IL147697A0 (en) Phosphate transport inhibitors
HUP0002103A3 (en) Hmg-coa reductase inhibitor preparation process
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
HUP0203682A3 (en) Method for administering a phosphodiesterase 4 inhibitor
AUPP912299A0 (en) Fuel enhancer
AU3761400A (en) Amino-thio-acrylonitriles as mek inhibitors
AU9443898A (en) Wof inhibitor
AU7125700A (en) Enzyme inhibitors
GB9924522D0 (en) Enzyme inhibitors
AU3235100A (en) Prothease inhibitors
AU6422798A (en) Stabilized urease inhibitor
AU7887100A (en) Corrosion inhibitor
GB2389113B (en) B-secretase inhibitor
AU3673000A (en) Agents for ameliorating pancreatic function disorder
ZA985179B (en) Process for producing medicaments which comprise HMG CoA reductase inhibitors
PL354454A1 (en) Enzymatic graying inhibitor
AU5289398A (en) Steel for cold forming
ZA200109203B (en) VLA-4 inhibitor compounds.
AUPO895897A0 (en) Steel versatile workhorse